Advanced Bifurcation Systems (ABS), a medical stenting technology company, today announced plans to increase their footprint in Asian markets through partnerships in the region.
March 14, 2018 - Newport Beach, California – Advanced Bifurcation Systems (ABS), a medical stenting technology company, today announced plans to increase their footprint in Asian markets through partnerships in the region. The company has been developing a revolutionary stenting technology that has the potential to simplify such procedures and reduce the financial burden on healthcare systems.
The announcement of their Asian strategy coincides with an ambitious new investment fundraising campaign. CEO Charles Laverty has set a goal of raising an additional $20 million in funds which the company will use to fund clinical trials and to apply for regulatory approval within the next.
The company’s Chief Medical Officer, Dr. Mehran Khorsandi, believes that Asian healthcare systems are natural partners for ABS due to their steadily increasing rates of heart disease. In China for example, heart disease affects 1 out of every 5 adults. There’s a clear need for new and innovative medical solutions such as the one developed by ABS.
Their system is a new stenting procedure that’s designed to treat bifurcation lesions in cardiac patients. A dual catheter is used to place stents in both the mother and daughter arteries at the same time. The system reduces the amount of errors and simplifies the procedure. Trials so far have been highly successful.
The Asian market represents a great opportunity for ABS and Laverty considers it essential to the company’s success. Almost 60% of the world’s population lives in the region and those numbers are projected to rise in the coming decades. It’s a major market and the company believes their technology may help it to improve treatment of heart disease and could potentially reduce the need for major surgeries.
CEO Laverty has plans to visit Asia several more times in the next year in a bid to strengthen its relationship with its new Asian partners. It’s also working to develop new ones. It’s all part of a coherent global growth strategy.
The company has announced plans for growth in 2018. Thomas O’Neill joined the ABS Board early this year. Mr. O’Neill co-founded Sandler O’Neill + Partners, leading practice groups financial institutions such as Rothschild and Bear Stearns. His extensive Board experience includes time serving for Nasdaq, The Archer Daniels Midland Company and First Allied. The company says it expects to announce more additions to its Board and new executive appointments this year.
About Advanced Bifurcation Systems
Advanced Bifurcation Systems is an innovator in the medical device industry. Its medical stenting technology could potentially alter the landscape significantly in the treatment of coronary angioplasties. Their seamless method for stenting branched arteries is a unique approach that has the backing of many medical experts. More information about the company and their new technology can be found on their website at www.advancedbifurcation.com.
Contact:
Advanced Bifurcation Systems
Charles Laverty
Chief Executive Officer
info@advancedbifurcation.com
(949)432-4824
